Sanofi Stock News

AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease Contro

Following another shaky day in the market, investors may want to consider cash cow dividend stocks. They're not sexy and they probably won't make you rich.

Drugmaker Sanofi's consumer healthcare division has attracted interest from private equity funds as the French group prepares to spin out the business, two sources close to the matter told Reuters.

Sanofi SA (EPA: SAN) is gaining at writing following a report that buyout firms have shown interest in buying its consumer health unit.

Denali Therapeutics said on Friday it was informed by partner Sanofi that their drug for a type of neurological disease did not meet the main goal in a mid-stage trial.

Not every stock has been swept up in the stock market's euphoria. Shares of Medtronic and Sanofi have been more muted lately.

Sanofi (SNY) Q4 2023 Earnings Call Transcript

Sanofi (SNY) Q4 2023 Earnings Call Transcript

TEVA reports better-than-expected fourth-quarter results, beating both earnings and sales estimates. The stock gains 3% in response.

Sanofi's fourth-quarter operating income declined 5% as a weaker U.S. dollar and cheaper rivals competing against its established multiple sclerosis drug outweighed growing sales of anti-inflammatory

The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, t

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Inhibrx (INBX) shares jumped over 7% in early trading Tuesday after Sanofi (SNY) said it would buy Inhibrx in a $1.7 billion deal as the French pharmaceutical giant expands its pipeline of drugs to tr

Sanofi plans to buy assets from U.S. biopharmaceutical company Inhibrx in a deal valued at up to $2.2 billion.

French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday.